AMNEAL PHARMACEUTICALS, INC. CLASS A COMMON STOCK

NYSE: AMRX (Amneal Pharmaceuticals, Inc.)

Last update: 2 hours ago

8.21

0.12 (1.48%)

Previous Close 8.09
Open 8.11
Volume 1,772,854
Avg. Volume (3M) 1,942,365
Market Cap 3,775,442,432
Price / Sales 0.900
52 Weeks Range
6.32 (-23%) — 9.48 (15%)
Earnings Date 8 Aug 2025 - 13 Aug 2025
Profit Margin -0.46%
Operating Margin (TTM) 14.51%
Diluted EPS (TTM) -0.040
Quarterly Revenue Growth (YOY) 5.50%
Quarterly Earnings Growth (YOY) -49.70%
Current Ratio (MRQ) 1.40
Operating Cash Flow (TTM) 306.92 M
Levered Free Cash Flow (TTM) 311.48 M
Return on Assets (TTM) 6.67%
Return on Equity (TTM) -881.26%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bearish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bearish Mixed
Stock Amneal Pharmaceuticals, Inc. Mixed Mixed

AIStockmoo Score

2.3
Analyst Consensus -2.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 5.0
Technical Oscillators 4.0
Average 2.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
AMRX 4 B - - -
ELAN 5 B - 15.35 1.12
PRGO 4 B 3.08% - 0.830
EBS 343 M - - 0.660
ZTS 71 B 1.16% 28.85 15.05
TAK 48 B 1,309.29% 34.98 0.980

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value
% Held by Insiders 46.75%
% Held by Institutions 44.24%

Ownership

Name Date Shares Held
Blackbarn Capital Partners Lp 31 Mar 2025 2,881,654

No data within this time range.

Date Type Details
25 Jun 2025 Announcement Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
12 Jun 2025 Announcement Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
29 May 2025 Announcement Amneal to Participate at Upcoming Investor Conferences in June
15 May 2025 Announcement Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
08 May 2025 Announcement Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
02 May 2025 Announcement Amneal Reports First Quarter 2025 Financial Results
11 Apr 2025 Announcement Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
08 Apr 2025 Announcement Amneal to Report First Quarter 2025 Results on May 2, 2025
07 Apr 2025 Announcement Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
03 Apr 2025 Announcement Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
01 Apr 2025 Announcement Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria